

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,611
				Filing Date	November 21, 2001
				First Named Inventor	Lorraine Faxon Meisner
				Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	1	Of	6	Attorney Docket Number	36091-701.302

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	2001/0041193 A1	11-15-2001	Meisner	
	2.	2002/0037314 A1	03-28-2002	Meisner	
	3.	2002/0164386 A1	11-07-2002	Meisner	
	4.	2005/0003023 A1	01-06-2005	Meisner	
	5.	2006/0165819 A1	07-27-2006	Meisner	
	6.	2008/0125395 A1	05-29-2008	Meisner	
	7.	2,400,171	05-14-1946	Ruskin et al.	
	8.	2,442,461	06-01-1948	Karrer	
	9.	3,857,970	12-31-1974	Tsumura, et al.	
	10.	3,886,265	05-27-1975	Evers et al.	
	11.	4,229,430	10-21-1980	Fahim et al.	
	12.	4,294,852	10-13-1981	Wildnauer et al.	
	13.	4,367,157	01-04-1983	Sherman	
	14.	4,515,771	05-07-1985	Fine	
	15.	4,590,067	05-20-1986	Meisner	
	16.	4,647,453	03-03-1987	Meisner	
	17.	4,711,780	12-08-1987	Fahim	
	18.	4,722,936	02-02-1988	Jacob	
	19.	4,772,591	09-20-1988	Meisner	
	20.	4,818,521	04-04-1989	Tamabuchi	
	21.	5,700,451	12-23-1997	Yue, et al.	
	22.	5,703,122	12-30-1997	Duffy	
	23.	5,736,567	04-07-1998	Cantin et al.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,611
				Filing Date	November 21, 2001
				First Named Inventor	Lorraine Faxon Meisner
				Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	2	Of	6	Attorney Docket Number	36091-701.302

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	24.	5,750,123	05-12-1998	Znaiden et al.	
	25.	5,972,993	10-26-1999	Ptchelintsev	
	26.	6,440,465	08-27-2002	Meisner	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
	27.	EP 0273202	06-21-1995	Van Scott		
	28.	EP 0771557	08-18-1999	L'Oreal		
	29.	JP 61078715 (English language abstract)	04-22-1986	Shiseido Co. Ltd.		AB
	30.	WO 98/23152	06-04-1998	Perricone		
	31.	WO 00/56327	09-28-2000	Bioderm, Inc.		
	32.	WO 01/83031	11-08-2001	Bioderm, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	33.	BANDELIN & TUSCHHOFF, "The Stability of Ascorbic Acid in Various Liquid Media", <i>J. Am. Pharmacol. Assoc.</i> 44(4):241-244 (1955)
	34.	BAUERNFEIND, "Ascorbic Acid Technology" in ASCORBIC ACID: CHEMISTRY, METABOLISM, AND USES, 417-29 (Seib & Tolbert, eds., American Chemical Society 1982)
	35.	BEKESI et al., "Inhibitory Effect of D-Glucosamine and Other Sugar Analogs on the Viability and Transplantability of Ascites Tumor Cells", <i>Cancer Research</i> 29:353-359 (1969)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	09/990,611	
			Filing Date	November 21, 2001	
			First Named Inventor	Lorraine Faxon Meisner	
			Art Unit	1616	
Examiner Name	Frank I. Choi				
Sheet	3	Of	6	Attorney Docket Number	36091-701.302

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	36.	BLACK, "Potential Involvement of Free Radical Reactions in Ultraviolet Light-Mediated Cutaneous Damage", <i>Photochemistry and Photobiology</i> 46:213-221 (1987)
	37.	BORNE & PEDEN "Antiinflammatory Activity of Para-Substituted N-Benzenesulfonyl Derivatives of Amino Acids", <i>J. Med. Chem.</i> 15(12):1325-1326 (1972)
	38.	COOKE & MOXON, "The Detection and Measurement of Vitamin C", in VITAMIN C (ASCORBIC ACID), 167-168, 170-171 (Counsell & Hornig, eds., Applied Science Publishers 1981)
	39.	ENGLAND & SEIFTER, "The Biochemical Functions of Ascorbic Acid", <i>Ann. Rev. Nutri.</i> 6:365-406 (1986)
	40.	GUALANO et al., "Anti-inflammatory Activity of S-Adenosyl-L-Methionine: Interference with the Eicosanoid System", <i>Pharmacology Res. Commun.</i> 15(7):683-695 (1983)
	41.	HAJRATWALA, "Stability of Ascorbic Acid", <i>S.T.P. Pharma</i> , 1(4):281-286 (1985)
	42.	HALL et al., "Anti-Inflammatory Activity of Diazomethyl Ketone and Chloromethyl Ketone Analogs Prepared from N-Tosyl Amino Acids", <i>J. Pharm. Sci.</i> 69(12):1451-1452 (1980)
	43.	HORNIG & MOSER, "The Safety of High Vitamin C Intakes in Man", in VITAMIN C (ASCORBIC ACID) 225-226 (Counsell & Hornig, eds., Applied Science Publishers 1981)
	44.	IMAI et al., "The Antiscorbutic Activity of L-Ascorbic Acid Phosphate Given Orally and Percutaneously in Guinea Pigs", <i>Jap. J. Pharmacol.</i> 317-324 (1967)
	45.	JAIN & KHANNA, "Evaluation of Anti-inflammatory and Analgesic Properties of L-Glutamine", <i>Agents and Actions</i> 11(3):243-248 (1981)
	46.	KAHN et al., "Ultraviolet Light Protection by Several New Compounds", <i>Arch Dermatol.</i> 109: 510-517 (1974)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,611
				Filing Date	November 21, 2001
				First Named Inventor	Lorraine Faxon Meisner
				Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	4	Of	6	Attorney Docket Number	36091-701.302

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	47.	KAPLAN et al., "A New Stabilized Ascorbic Acid Solution: Percutaneous Absorption and Effect on Relative Collagen Synthesis", <i>J. Cutaneous Aging & Cosmetic Derm.</i> 1(2):115-121 (1988/89)
	48.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: III. Effect of Metal-complexing Agents", <i>Pharma. Acta Helveticae</i> 47:89-97 (1972)
	49.	KASSEM et al., "Studies on the Stability of Injectable L-Ascorbic Acid Solutions: I. Effect of pH, Solvent, Light and Container", <i>Pharmaceutica Acta Helveticae</i> 44:611-623 (1969)
	50.	KOLATA, "Is Tyrosine the Key to Growth Control?" <i>Science</i> 219:377-378 (1983)
	51.	KUNERT & TAPPEL, "The Effect of Vitamin C on in vivo Lipid Peroxidation in Guinea Pigs as Measured by Pentane and Ethane Production", <i>Lipids</i> 18(4):271-273 (1983)
	52.	KWAPISZEWSKI et al., "Synthesis of L-Cysteine and S-Methyl-L-Cysteine Derivatives of Immunotropic and Anti-inflammatory Activity", <i>Arch. Immunol. Et Ther. Exp.</i> 27(6):729-731 (1979)
	53.	LASZLO et al., "Effects of Glucose Analogues (2-Deoxy-D-glucose, 2-Deoxy-D-galactose) on Experimental Tumors", <i>Journal of the National Cancer Institute</i> 24(2):267-278 (1960)
	54.	LIEN et al., "Topical Use of Ascorbic Acid in the Management of Pressure Sore", <i>J. Formosan Med. Assoc.</i> , 75:243-250 (1976)
	55.	LITWIN, "Growth of Human Diploid Fibroblasts in Media with Different Amino Acid Composition", <i>J. Cell Science</i> 14:671-680 (1974)
	56.	NOBILE et al., VITAMIN C: THE MYSTERIOUS REDOX-SYSTEM A TRIGGER OF LIFE?, 23-24 (MIP Press Ltd., Boston, MA 1981)
	57.	PINNELL & MURAD, "Vitamin C and Collagen Metabolism," in CUTANEOUS AGING, 275-292 (Kligman & Tukase, eds. Univ. of Tolyo Press 1988)

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,611
				Filing Date	November 21, 2001
				First Named Inventor	Lorraine Faxon Meisner
				Art Unit	1616
Examiner Name	Frank I. Choi				
Sheet	5	Of	6	Attorney Docket Number	36091-701.302

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	SETNIKAR et al., "Antireactive Properties of Glucosamine Sulfate," <i>Arzneimittel Forschung Drug Research</i> 41:157-161 (1991)
	59.	SMART et al., "Inhibition of 12-O-Tetradecanoylphorbol-13-acetate Induction of Ornithine Decarboxylase Activity, DNA Synthesis, and Tumor Promotion in Mouse Skin by Ascorbic Acid and Ascorbyl Palmitate", <i>Cancer Res.</i> 47:6633-6638 (1987)
	60.	TAPADINHAS et al., "Oral Glucosamine Sulphate in the Management of Arthrosis: Report on a Multi-centre Open Investigation in Portugal", <i>Pharmatherapeutica</i> 3(3):157-168 (1982)
	61.	THE MERCK INDEX: AN ENCYCLOPEDIA OF CHEMICALS AND DRUGS, 110-111 (#845-858) (Windholz, et al. eds., Merck and Co., 9th ed. 1976)
	62.	THOMAS et al., "Anti-inflammatory Activity of Esters of Phenylglycine", <i>Communications J. Pharm. Pharmacol.</i> 26:151-152 (1974)
	63.	WEST & TODD, TEXTBOOK OF BIOCHEMISTRY 795 (The MacMillan Company, New York 1951)
	64.	Office Action mailed February 29, 2008 in connection with U.S. Patent Application No. 09/997,663, assigned to Bioderm, Inc., under examination by Examiner Choi at the USPTO
	65.	Claims pending on February 29, 2008 in connection with U.S. Patent Application No. 09/997,663, assigned to Bioderm, Inc., under examination by Examiner Choi at the USPTO
	66.	Office Action mailed June 13, 2006 in connection with U.S. Patent Application No. 10/614,768, assigned to Bioderm, Inc., now abandoned
	67.	Claims pending on June 13, 2006 in connection with U.S. Patent Application No. 10/614,768, assigned to Bioderm, Inc., now abandoned
	68.	Office Action mailed November 5, 2007 in connection with U.S. Patent Application No. 11/389,384, assigned to Bioderm, Inc., now abandoned

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08 (07/05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/990,611
				Filing Date	November 21, 2001
				First Named Inventor	Lorraine Faxon Meisner
				Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	6	Of	6	Attorney Docket Number	36091-701.302

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	69	Claims pending on November 5, 2007 in connection with U.S. Patent Application No. 11/389,384, assigned to Bioderm, Inc., now abandoned
	70	Office Action mailed November 2, 2007 in connection with U.S. Patent Application No. 10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO
	71	Claims pending on November 2, 2007 in connection with U.S. Patent Application No. 10/185,388, assigned to Bioderm, Inc., under examination by Examiner Flood at the USPTO

Examiner Signature	/Frank Choi/	Date Considered	04/06/2009
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.